| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Tetracaine HCl Basic Information:
Pharmaceutical-Grade Anesthetic Purity HCl Powder | CAS 136-47-0 | Tetracaine Lidocaine
Lidocaine hydrochloride undergoes rapid metabolism in the liver, with both metabolites and unchanged drug being excreted by the kidneys. The biotransformation process includes oxidative N-dealkylation, ring hydroxylation, amide bond cleavage, and conjugation. N-dealkylation, the primary pathway, produces the metabolites monoethylglycinexylidide and glycinexylidide. These metabolites exhibit pharmacological and toxicological actions similar to Lidocaine hydrochloride, though they are less potent. Approximately 90% of administered Lidocaine hydrochloride is excreted as various metabolites, with less than 10% excreted unchanged. The main metabolite found in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline.
Lidocaine HCl: A Premier Amide Local Anesthetic.
As the dosage increases, both efficacy and potential toxicity rise. At sub-toxic plasma concentrations, Lidocaine HCl also possesses anti-convulsive effects.
Blood concentrations exceeding 5μg/ml can result in convulsions.
){kind=link}